AlloMek Therapeutics is a privately held company focused on developing macrocycles for treating rare diseases.
AlloMek’s most advance candidate, CIP-137401, is an IND ready molecule which works by inhibiting MEK Kinase, an important target implicated in various rare diseases including cancer.